Financial Reports

8 stories about Financial Reports
בורסה תל אביב מסחר

How dual-listed companies boost profits without earning more

08.12.24|Uri Tal Tenne
The creative accounting tricks Israeli firms use to inflate earnings.
מטה וויקס Wix תל אביב

Wix returns to $10 billion valuation amid strong revenue growth

20.11.24|Sophie Shulman
Bookings rise 15% as the company accelerates its path to $2 billion in annual revenue.
ערן זינמן ו רועי מן מייסדי מאנדיי

Monday.com eyes $200M office lease in Tel Aviv amid growth in revenue and personnel

30.10.24|Sophie Shulman
The tech firm’s move to lease 30 floors in Azrieli’s newest skyscraper in a 10-year deal reflects its skyrocketing ARR and aggressive expansion plans for a 2,500-strong workforce.
הנהלת  מאנדיי קום  MONDAY COM

Monday.com tops estimates, registers operating profit for first time

12.08.24|Sophie Shulman
The Israeli software company ended the second quarter with an operating profit of $1.8 million, compared to a loss of $12.2 million in the corresponding period. The company raised its total revenue forecast for 2024 to nearly $1 billion.
הנפקת מובילאיי

Mobileye announces 38% increase in revenue to $450 million in first report since IPO

07.12.22|Sophie Shulman
The Israeli company's first report since its split from Intel revealed that most of its revenue still comes from assistance and alert systems and not from fully autonomous vehicle systems
מגזין עצמאות 4.5.22 בכירי ריסקיפייד פותחים את המסחר בניו יורק

The secret behind the surprise success of Monday, Fiverr and Riskified

16.11.22|Sophie Shulman
Israeli-founded SaaS companies published extremely positive results for the third quarter of the year, but they should not necessarily be seen as a signal for continued improvement in 2023
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants

16.05.19|Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?